Several randomized clinical trials have analyzed the effect of SGLT2 inhibitors on glycemic control and cardiovascular and renal outcomes in patients with T2D [9,22,23,24,25,26]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.